Nicklas Westerholm - EGETIS THERAPEUTICS Chief Executive Officer
| P0F Stock | EUR 0.32 0.01 3.03% |
CEO
Nicklas Westerholm is Chief Executive Officer of EGETIS THERAPEUTICS AB since 2017.
| Age | 41 |
| Tenure | 8 years |
| Phone | 46 86 79 72 10 |
| Web | http://www.egetis.com |
Similar Executives
| Found 2 records | CEO Age | ||
| David Farias | Jacquet Metal Service | N/A | |
| Philippe Goczol | Jacquet Metal Service | 57 | |
Management Performance
| Return On Equity | -0.26 | |||
| Return On Asset | -0.14 |
EGETIS THERAPEUTICS Leadership Team
Elected by the shareholders, the EGETIS THERAPEUTICS's board of directors comprises two types of representatives: EGETIS THERAPEUTICS inside directors who are chosen from within the company, and outside directors, selected externally and held independent of EGETIS. The board's role is to monitor EGETIS THERAPEUTICS's management team and ensure that shareholders' interests are well served. EGETIS THERAPEUTICS's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, EGETIS THERAPEUTICS's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Peter Walberg, Executive Director, Interim Chief Medical Officer | ||
| Sten Nilsson, Director | ||
| Marie Bengtson, Clinical Project Director | ||
| Henrik Krook, Vice President - Commercial Operations | ||
| Gunilla Osswald, Director | ||
| Malin Nittve, Project Manager, Director of Regulatory Affairs | ||
| Marie Tragardh, Director | ||
| Christian Sonesson, Vice President Product Strategy and Development | ||
| Jacques Nasstrom, Vice President Preclinical Research & Development, Chief Scientific Officer | ||
| Elisabeth Svanberg, Director | ||
| Hakan Astrom, Chairman of the Board | ||
| Dennis Henriksen, Project Manager Aladote | ||
| Stefan Carlsson, Chief Medical Officer, Vice President | ||
| Sven Jacobsson, Head of Chemistry, Manufacturing and Control (CMC) | ||
| Yilmaz Mahshid, Chief Financial Officer | ||
| Nicklas Westerholm, Chief Executive Officer | ||
| MarieLouise Alamaa, Interim Chief Financial Officer |
EGETIS Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is EGETIS THERAPEUTICS a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.26 | |||
| Return On Asset | -0.14 | |||
| Shares Outstanding | 214.59 M | |||
| Shares Owned By Insiders | 60.64 % | |||
| Shares Owned By Institutions | 11.79 % | |||
| Gross Profit | (58.28 M) | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 3.54 X | |||
| Number Of Employees | 17 | |||
| Beta | 1.18 |
Currently Active Assets on Macroaxis
Other Information on Investing in EGETIS Stock
EGETIS THERAPEUTICS financial ratios help investors to determine whether EGETIS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in EGETIS with respect to the benefits of owning EGETIS THERAPEUTICS security.